The Guardian is reaching out to individuals for whom GLP-1 receptor agonist drugs, including Wegovy and Mounjaro, have proven ineffective. Approximately 5-10% of people who try these medications fall into this category, according to clinical data. The publication invites readers to share their personal stories, whether the drugs caused unbearable side effects, provided no benefit despite prolonged use, or led to stigma. The call also seeks to know what alternative approaches people are now pursuing to achieve the hoped-for outcomes.
Share Your Experience
Participants aged 18 and over can contribute via an online form, anonymously if desired. The Guardian assures that responses are secure, encrypted, and accessible only to the news organization. Personal data will be used solely for the feature and deleted once no longer required. For alternative secure contact methods, the tips guide is available. Those encountering issues with the form can click for assistance, and terms of service and privacy policy are provided for reference.
Understanding GLP-1 Non-Response
GLP-1 drugs, originally developed for type 2 diabetes, have gained popularity for weight loss. However, a minority of users do not experience significant weight reduction or find the side effects—such as nausea, vomiting, and diarrhea—intolerable. The Guardian aims to highlight these experiences to better understand the limitations of these treatments and the challenges faced by non-responders.
